Correlation of Campbell Score With Suicidal Ideation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04606875 |
Recruitment Status :
Recruiting
First Posted : October 28, 2020
Last Update Posted : October 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The Campbell Score is a blood based means of assessing molecules believed to be associated with suicidal ideation and in some cases successful suicide.
The current clinical trial will assess the Campbell Score in 3 groups:
Group 1: 10 patients with no personal or family psychiatric history and no suicide attempts.
Group 2: 10 patients with suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20).
Group 3: 10 patients with suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60).
The goal of the study is to confirm efficacy of Campbell Score in identifying patients with high suicidal ideation potential.
Condition or disease | Intervention/treatment |
---|---|
Suicidal Ideation | Diagnostic Test: Campbell Score |
Study Type : | Observational |
Estimated Enrollment : | 30 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Assessment of Campbell Score as a Means of Predicting Suicidal Ideation High Risk Patients |
Estimated Study Start Date : | November 5, 2020 |
Estimated Primary Completion Date : | January 13, 2021 |
Estimated Study Completion Date : | February 13, 2021 |
Group/Cohort | Intervention/treatment |
---|---|
Control Group
Subjects will have no personal or family psychiatric history and no suicide attempts.
|
Diagnostic Test: Campbell Score
The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations. |
Patients with Suicidal Ideation and Low Acquired Capability
Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
|
Diagnostic Test: Campbell Score
The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations. |
Patients with Suicidal Ideation and High Acquired Capability
Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
|
Diagnostic Test: Campbell Score
The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations. |
- Assessment of Campbell Score [ Time Frame: 1 week to compare the records with the Campbell Score ]Campbell Score will be compared between healthy volunteers, patients with suicidal idea with low acquired capability for suicide, and patients with suicidal idea with high acquired capability for suicide.
- Assessment of Correlation between Campbell Score and Beck Scale for Suicidal Ideation [ Time Frame: 1 week to compare the records with the Campbell Score ]Campbell Score will be compared to scoring of patients on the Beck Scale for Suicidal Ideation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Capability of giving informed consent
- Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study.
- Be diagnosed with Suicide ideation/attempts/gestures
Exclusion Criteria:
- Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04606875
Contact: Famela Ramos | 619 246 9179 | famela8@gmail.com |
United States, California | |
Therapeutic Solutions International | Recruiting |
Oceanside, California, United States, 92056 | |
Contact: Famela Ramos 619-246-9179 famela8@gmail.com | |
Principal Investigator: James Veltmeyer, MD |
Responsible Party: | Therapeutic Solutions International |
ClinicalTrials.gov Identifier: | NCT04606875 |
Other Study ID Numbers: |
Campbell Neuro 001 |
First Posted: | October 28, 2020 Key Record Dates |
Last Update Posted: | October 28, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
interleukin-6, suicidal ideation, immunology |
Suicidal Ideation Suicide Self-Injurious Behavior Behavioral Symptoms |